US Pharma MarketingThe post Novo Nordisk reports Phase III FRONTIER4 study results for denecimig appeared first on Clinical Trials Arena.
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy of investigational Mim8 in patients with haemophilia A. The interim analysis included 426 participants aged one year and above. The trial evaluates denecimig as subcutaneous prophylaxis in all ages with or without inhibitors. Credit: SaiArLawKa2 / Shutterstock.com. Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy of investigational denecimig (Mim8) in patients with haemophilia A. The open-label trial is evaluating denecimig as a subcutaneous prophylactic treatment in children, adolescents,…
Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy of investigational Mim8 in patients with haemophilia A.
Source: Clinical Trials Arena